Table 1.

Summary of adverse events of the SAD study considered probably or possibly related to study treatment

	PRI‐002
	Cohort 1 (4 mg)	Cohort 2 (12 mg)	Cohort 3 (36 mg)	Cohort 4 (108 mg)	Cohort 5 (320 mg)	Placebo	Total
System organ class, preferred term, n (%)	n = 6	n = 6	n = 6	n = 6	n = 6	n = 10	n = 40
Nervous system disorders
EEG abnormal (grade 1)	1	1	3	0	0	3	8
	(16.7%)	(16.7%)	(50.0%)			(30%)	(20%)
Headache (grade 2)	0	0	1	0	0	0	1
			(16.7%)				(2.5%)
Total number of events	1	1	4	0	0	3	9
	(16.7%)	(16.7%)	(66.7%)			(30%)	(22.5%)